20 articles
A comprehensive review of in vitro assays for inducing cellular senescence and screening senolytic drugs, highlighting key challenges in clinical translation.
Fucoidan, dasatinib+quercetin, and MitoQ each counteract hyperoxia-driven cellular senescence in fetal airway cells via distinct mechanisms.
A new study pinpoints chemotherapy-induced senescent bone marrow cells as the culprit behind bone loss, and shows senolytics can prevent it.
A phase 1 trial of dasatinib + quercetin in 5 early AD patients uncovers fluid biomarker changes that could guide future senolytic trials.
4-month senolytic treatment with D+Q cleared senescent RPE cells, reduced lipofuscin, and preserved vision in a preclinical dry AMD model.
A senolytic pairing of dasatinib and quercetin cleared senescent cells at the tendon-bone junction, dramatically improving repair strength in aged rats.
A novel anti-swelling hydrogel loaded with dasatinib, quercetin, and nucleus pulposus exosomes clears senescent cells and restores disc integrity in rats and goats.
Dasatinib and quercetin clear senescent cochlear cells, reducing inflammation and preserving hair cells in aging mice.
Comprehensive review identifies senolytics, NAD+ precursors, mTOR inhibitors and other compounds targeting aging hallmarks.
Dive deep into partial reprogramming, niche remodeling, senolytics, and cutting-edge clinical therapies — the molecular toolkit for reversing stem cell aging.
Master the cutting-edge molecular targets, clinical trial data, and emerging therapeutic strategies aimed at reversing ECM aging — from senolytic combinations to biomaterial scaffolds and epigenetic reprogramming.
Dasatinib and quercetin, a leading senolytic combo, unexpectedly reduced myelination in healthy mouse brains, mimicking multiple sclerosis damage.
Dasatinib plus quercetin cleared senescent cells and reduced inflammation, improving alveolar bone health in aged mice.
Explore the molecular mechanisms of cellular senescence and how p16/p21 pathways drive SASP production, plus cutting-edge senolytic drug targets.
Review reveals how anti-cancer drugs are being repurposed to eliminate senescent cells, opening new pathways for longevity treatments.
Alendronate-modified liposomes carrying dasatinib and quercetin doubled bone volume in chemotherapy-induced osteoporosis models.
New research reveals how aging liver cells release harmful vesicles that promote cancer metastasis across multiple tumor types.
Researchers develop BH3 profiling to predict senolytic drug effectiveness, moving beyond one-size-fits-all aging treatments.
Dasatinib and quercetin nanoparticles improve egg quality and fertility in aging mouse ovaries by clearing senescent cells.
New review reveals senolytic therapies can both help and harm cardiovascular health, challenging clinical translation.
